<DOC>
	<DOCNO>NCT00704392</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability , high safe dos XL647 combination XL147 adult solid tumor . XL647 small molecule potently inhibit multiple receptor kinase , include EGFR , VEGFR2 ( KDR ) , ErbB2 . XL147 new chemical entity inhibit PI3 Kinase . Inactivation PI3K show inhibit growth induce apoptosis ( program cell death ) tumor cell .</brief_summary>
	<brief_title>Safety Study XL647 XL147 Administered Combination Daily Adults With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>The subject histologically confirm solid tumor metastatic unresectable long respond therapy know prolong survival standard therapy , disease standard therapy exists . The subject ≥ 18 year old . The subject 's weight ≥ 50 kg . The subject Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 . The subject life expectancy ≥ 3 month . The subject adequate organ marrow function . The subject fasting plasma glucose ( FPG ) &lt; 120 mg/dL screening . The subject capable understanding comply protocol sign informed consent document . Sexually active subject ( male female ) must agree use accept method contraception course study 3 month last dose protocol drug ( ) . Female subject childbearing potential must negative pregnancy test screening . Subjects MTD Expansion Cohort : Must measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) . Must histologically confirm diagnosis NSCLC ( Stage IIIB IV ) OR histologically confirm diagnosis metastatic breast cancer . The subject receive cytotoxic chemotherapy ( include investigational cytotoxic chemotherapy ) within 3 week ( nitrosoureas mitomycin C within 6 week ) first dose XL647 . The subject receive prior treatment small molecule kinase inhibitor ( include investigational kinase inhibitor ) within 14 day first dose XL647 . The subject receive type investigational agent within 30 day first dose study treatment . The subject recover toxicity due prior therapy . The subject major surgery within 30 day first dose study drug . Subjects must recover stabilized prior surgery . The subject know diabetes . The subject currently receive anticoagulation warfarin ( lowdose warfarin ≤ 1mg/day , heparin , lowmolecular weight heparin permit ) . The subject prothrombin time ( PT ) /International Normalized Ratio ( INR ) /or partial thromboplastin time ( PTT ) test result screen 1.3 time laboratory upper limit normal . The subject follow cardiac criterion : Corrected QT interval ( QTc ) &gt; 0.46 second Has finding leave bundle branch block Has important bradycardia define heart rate &lt; 50 bpm due sinus node dysfunction Has obligate pacemaker History sustain ventricular arrhythmia ( subject history atrial arrhythmia discuss sponsor entry study ) Family history congenital long QT syndrome unexplained sudden death Has uncontrolled hypertension Has symptomatic congestive heart failure , unstable angina , myocardial infarction within past 3 month The subject require treatment drug know associated torsades de pointes significant QT interval prolongation . The subject serum potassium level serum magnesium level fall outside normal range . The subject know brain metastasis primary brain tumor . The subject intercurrent illness include limited ongoing active infection . The subject know positive human immunodeficiency virus ( HIV ) . The subject pregnant breastfeeding . The subject previously identify allergy hypersensitivity component study treatment formulation The subject unable unwilling abide study protocol cooperate fully investigator designee</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Solid tumor</keyword>
	<keyword>NSCLC</keyword>
</DOC>